These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19763387)

  • 61. Living Donor Liver Transplantation Versus Deceased Donor Liver Transplantation for Hepatocellular Carcinoma Within or Beyond the Milan Criteria: Comparable Long-Term Outcomes.
    Lee S; Song GW; Kim KW; Kwon JH; Lee SG
    Transplant Proc; 2021; 53(1):92-97. PubMed ID: 33288309
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Living donor liver transplantation for hepatocellular carcinoma: the Japanese experience.
    Tamura S; Sugawara Y; Kokudo N
    Oncology; 2011; 81 Suppl 1():111-5. PubMed ID: 22212944
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation.
    Sharr WW; Chan SC; Lo CM
    Transplantation; 2014 Apr; 97 Suppl 8():S10-7. PubMed ID: 24849822
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The impact of Milan criteria on liver transplantation for hepatocellular carcinoma: first 15 years' experience of the Hungarian Liver Transplant Program.
    Nemes B; Gelley F; Piros L; Zádori G; Görög D; Fehérvári I; Kóbori L; Sárváry E; Nagy P; Kiss A; Doros A
    Transplant Proc; 2011 May; 43(4):1272-4. PubMed ID: 21620108
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prospective study on the outcome of patients with hepatocellular carcinoma registered for living donor liver transplantation: how long can they wait?
    Mizuno S; Yokoi H; Shiraki K; Usui M; Sakurai H; Tabata M; Sugimoto K; Takei Y; Yamakado K; Takeda K; Uemoto S; Isaji S
    Transplantation; 2010 Mar; 89(6):650-4. PubMed ID: 20048691
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma.
    Takada Y; Ueda M; Ito T; Sakamoto S; Haga H; Maetani Y; Ogawa K; Kasahara M; Oike F; Egawa H; Tanaka K
    Liver Transpl; 2006 Jun; 12(6):912-9. PubMed ID: 16489583
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.
    An HJ; Jang JW; Bae SH; Choi JY; Yoon SK; Lee MA; You YK; Kim DG; Jung ES
    Liver Transpl; 2012 Dec; 18(12):1406-14. PubMed ID: 22821639
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A decade of right liver adult-to-adult living donor liver transplantation: the recipient mid-term outcomes.
    Chan SC; Fan ST; Lo CM; Liu CL; Wei WI; Chik BH; Wong J
    Ann Surg; 2008 Sep; 248(3):411-9. PubMed ID: 18791361
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hangzhou criteria for liver transplantation in hepatocellular carcinoma: a single-center experience.
    Lei JY; Wang WT; Yan LN
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):200-4. PubMed ID: 23995766
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Liver transplantation for hepatocellular carcinoma: defining the impact of using extended criteria liver allografts.
    Facciuto ME; Singh MK; Katta U; Samaniego S; Sharma J; Rodriguez-Davalos M; Sheiner P; Kim-Schluger L; Wolf DC
    Transplantation; 2011 Aug; 92(4):446-52. PubMed ID: 21694662
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Living donor liver transplantation for hepatocellular carcinoma: a single-center preliminary report.
    Malagó M; Sotiropoulos GC; Nadalin S; Valentin-Gamazo C; Paul A; Lang H; Radtke A; Saner F; Molmenti E; Beckebaum S; Gerken G; Frilling A; Broelsch CE
    Liver Transpl; 2006 Jun; 12(6):934-40. PubMed ID: 16528715
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation.
    Taketomi A; Sanefuji K; Soejima Y; Yoshizumi T; Uhciyama H; Ikegami T; Harada N; Yamashita Y; Sugimachi K; Kayashima H; Iguchi T; Maehara Y
    Transplantation; 2009 Feb; 87(4):531-7. PubMed ID: 19307789
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study.
    Shimamura T; Akamatsu N; Fujiyoshi M; Kawaguchi A; Morita S; Kawasaki S; Uemoto S; Kokudo N; Hasegawa K; Ohdan H; Egawa H; Furukawa H; Todo S;
    Transpl Int; 2019 Apr; 32(4):356-368. PubMed ID: 30556935
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Liver transplantation for hepatocellular carcinoma: results of a multicenter study with common priorization criteria.
    Santoyo J; Sanchez B; de la Mata M; Fernández-Aguilar JL; Lopez-Ciller P; Pascasio JM; Suarez MA; Gomez MA; Nogueras F; Muffak K; Cuende N; Alonso M
    Transplant Proc; 2009 Apr; 41(3):1009-11. PubMed ID: 19376412
    [TBL] [Abstract][Full Text] [Related]  

  • 75. How far can we go with hepatocellular carcinoma in living donor liver transplantation?
    Limkemann AJP; Abreu P; Sapisochin G
    Curr Opin Organ Transplant; 2019 Oct; 24(5):644-650. PubMed ID: 31397731
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Outcome of Liver Transplantation in Hepatocellular Carcinoma Patients at Siriraj Hospital.
    Kositamongkol P; Sanphasitvong V; Sirivatanauksorn Y; Pongpaibul A; Limsrichamrern S; Mahawithitwong P; Asavakarn S; Tovikkai C; Dumronggittigule W
    Transplant Proc; 2017 Jun; 49(5):1114-1117. PubMed ID: 28583538
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Liver transplantation for hepatocellular carcinoma.
    Mazzaferro V; Chun YS; Poon RT; Schwartz ME; Yao FY; Marsh JW; Bhoori S; Lee SG
    Ann Surg Oncol; 2008 Apr; 15(4):1001-7. PubMed ID: 18236119
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.
    Toso C; Meeberg G; Hernandez-Alejandro R; Dufour JF; Marotta P; Majno P; Kneteman NM
    Hepatology; 2015 Jul; 62(1):158-65. PubMed ID: 25777590
    [TBL] [Abstract][Full Text] [Related]  

  • 79. No-touch en bloc right lobe living-donor liver transplantation with inferior vena cava replacement for hepatocellular carcinoma close to retrohepatic inferior vena cava: case report.
    Moon DB; Lee SG; Hwang S; Kim KH; Ahn CS; Ha TY; Song GW; Jung DH; Park GC; Namkoong JM; Park HW; Park YH; Park CS
    Transplant Proc; 2013 Oct; 45(8):3135-9. PubMed ID: 24157050
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison between human-telomerase reverse transcriptase mRNA and alpha-fetoprotein mRNA as a predictive value for recurrence of hepatocellular carcinoma in living donor liver transplantation.
    Oya H; Sato Y; Yamamoto S; Nakatsuka H; Kobayashi T; Hara Y; Waguri N; Suda T; Aoyagi Y; Hatakeyama K
    Transplant Proc; 2006 Dec; 38(10):3636-9. PubMed ID: 17175353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.